Home › Compare › DIGAF vs JNJ

DIGAF vs JNJ: Dividend Comparison 2026

DIGAF yields 200000000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DIGAF wins by $4.875657285131069e+59M in total portfolio value
10 years
DIGAF
DIGAF
● Live price
200000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875657285131069e+59M
Annual income
$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full DIGAF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — DIGAF vs JNJ

📍 DIGAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDIGAFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DIGAF + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DIGAF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DIGAF
Annual income on $10K today (after 15% tax)
$17,000,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, DIGAF beats the other by $414,430,461,612,418,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DIGAF + JNJ for your $10,000?

DIGAF: 50%JNJ: 50%
100% JNJ50/50100% DIGAF
Portfolio after 10yr
$2.4378286425655345e+59M
Annual income
$243,782,624,477,893,130,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DIGAF
No analyst data
Altman Z
-72.3
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DIGAF buys
0
JNJ buys
0
No recent congressional trades found for DIGAF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDIGAFJNJ
Forward yield200000000.00% ✓2.14%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$4.875657285131069e+59M$30.5K ✓
Annual income after 10y$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$4,749.88
Total dividends collected$4.875656971401711e+59M$15.6K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DIGAF vs JNJ ($10,000, DRIP)

YearDIGAF PortfolioDIGAF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$20,000,010,700$20,000,000,000.00$10,594$274.49+$20000.00M → DIGAF
2$37,383,218,970,104,910$37,383,197,570,093,464.00$11,294$360.69+$37383218970.09M → DIGAF
3$65,303,942,472,059,150,000,000$65,303,902,472,014,860,000,000.00$12,133$476.91+$65303942472059152.00M → DIGAF
4$106,615,009,060,306,890,000,000,000,000$106,614,939,185,088,440,000,000,000,000.00$13,156$635.42+$1.0661500906030689e+23M → DIGAF
5$162,672,273,967,082,950,000,000,000,000,000,000$162,672,159,889,023,270,000,000,000,000,000,000.00$14,432$854.61+$1.6267227396708296e+29M → DIGAF
6$231,966,340,306,755,300,000,000,000,000,000,000,000,000$231,966,166,247,422,140,000,000,000,000,000,000,000,000.00$16,056$1,162.76+$2.319663403067553e+35M → DIGAF
7$309,138,182,305,146,600,000,000,000,000,000,000,000,000,000,000$309,137,934,101,162,400,000,000,000,000,000,000,000,000,000,000.00$18,175$1,604.53+$3.091381823051466e+41M → DIGAF
8$385,031,777,252,258,400,000,000,000,000,000,000,000,000,000,000,000,000$385,031,446,474,403,340,000,000,000,000,000,000,000,000,000,000,000,000.00$21,009$2,252.68+$3.850317772522584e+47M → DIGAF
9$448,184,411,799,345,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000$448,183,999,815,344,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$24,911$3,229.73+$4.481844117993459e+53M → DIGAF
10$487,565,728,513,106,900,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000$487,565,248,955,786,300,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$4.875657285131069e+59M → DIGAF

DIGAF vs JNJ: Complete Analysis 2026

DIGAF — Stock

Digatrade Financial Corp. operates as a financial technology services company. It develops proprietary patent-pending credit card payment platform to increase the security of online credit card payment processing. It also provides research and development related services in the digital-asset industry for prospective institutional customers, as well as focusing on blockchain and the financial technology sector unrelated to facilitating trading activities. The company was formerly known as Bit-X Financial Corporation and changed its name to Digatrade Financial Corp. in October 2015. Digatrade Financial Corp. was incorporated in 2000 and is headquartered in Vancouver, Canada.

Full DIGAF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DIGAF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DIGAF vs SCHDDIGAF vs JEPIDIGAF vs ODIGAF vs KODIGAF vs MAINDIGAF vs ABBVDIGAF vs MRKDIGAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.